由于美国食品药品监督管理局（FDA）拒绝批准其治疗眼部疾病的药物，Aldeyra Therapeutics Inc (ALDX) 的股价遭受重创，跌至历史最低点。盘中交易时段，该股跌幅一度高达70%，市场反应极为剧烈。
这一监管决定对公司的短期前景造成了重大打击，投资者信心严重受挫。股价的急剧下跌反映了市场对于该药物获批前景的突然转向以及公司未来收入预期的重新评估。
由于美国食品药品监督管理局（FDA）拒绝批准其治疗眼部疾病的药物，Aldeyra Therapeutics Inc (ALDX) 的股价遭受重创，跌至历史最低点。盘中交易时段，该股跌幅一度高达70%，市场反应极为剧烈。
这一监管决定对公司的短期前景造成了重大打击，投资者信心严重受挫。股价的急剧下跌反映了市场对于该药物获批前景的突然转向以及公司未来收入预期的重新评估。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.